Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Abivax    ABVX   FR0012333284

ABIVAX

(ABVX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Abivax : secures FDA approval for Phase I/II trial with ABX196 in HCC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 07:14am EST

Abivax and Scripps Research have secured approval from the US Food and Drug Administration (FDA) to start a Phase I/II clinical trial with ABX196 in patients with hepatocellular carcinoma (HCC).

The US regulator accepted an investigational new drug application for ABX196, which demonstrated potent efficacy in HCC animal models.

ABX196, an invariant Natural Killer T cell (iNKT) agonist, will be tested in combination with Bristol Myers Squibbs checkpoint inhibitor Opdivo (nivolumab) to treat HCC.

The clinical trial will be initiated this summer at Scripps MD Anderson Cancer Center in San Diego, California.

The study will also be carried out at further cancer centers in the US in the later expansion phase.

ABX196s potential for cancer therapy has been demonstrated in preclinical studies. Abivax said the synthetic glycolipid agonist, both alone and in combination with a checkpoint inhibitor, showed a statistically highly significant therapeutic effect in reducing tumor growth as measured by MRI and increasing survival in mice with HCC.

Abivax owns exclusive rights to ABX196 from Scripps Research, the University of Chicago, and Brigham Young University.

Abivax CEO Hartmut Ehrlich said: This open IND allows Abivax, in collaboration with leading key opinion leaders at internationally renowned US cancer centers of excellence, to explore the clinical potential of our iNKT agonist ABX196 to broaden and potentiate the activity of the checkpoint inhibitor nivolumab.

Based on its unique mechanism of action and exciting preclinical data in several cancer models, we believe ABX196 is a promising immunotherapeutic product candidate for patients with liver cancer that may also have potential in other cancers.

ABX196 is Abivax second compound in clinical development after its front-runner ABX464 for inflammatory diseases.

The company uses its antiviral and immune enhancing platforms to optimise candidates for the treatment of ulcerative colitis and other inflammatory diseases, viral diseases and liver cancer.

(c) 2003-2019 SudanTribune - All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ABIVAX
09/30ABIVAX : 2019 Half-Year Financial Report
PU
09/19ABIVAX : Half-year results
CO
08/19ABIVAX : First patient enrolled in Abivax ABX464-103 Phase 2b Clinical Trial in ..
PU
07/11ABIVAX : Completes €12 Million Capital Raise Entirely Subscribed by Sofinnova Pa..
PU
06/30ABIVAX : Half-year report
CO
05/16ABIVAX : secures FDA approval for Phase I/II trial with ABX196 in HCC
AQ
05/15ABIVAX : Registration Document 2019 (EN)
PU
05/14ABIVAX : and Scripps Research Announce FDA Approval to Initiate a Phase 1/2 Clin..
AQ
05/03ABIVAX : receives Phase IIb trial authorisation from Canada for ABX464
AQ
03/14ABIVAX : Annual results
CO
More news
Financials (EUR)
Sales 2019 0,28 M
EBIT 2019 -23,4 M
Net income 2019 -19,9 M
Finance 2019 0,70 M
Yield 2019 -
P/E ratio 2019 -7,99x
P/E ratio 2020 3,41x
EV / Sales2019 693x
EV / Sales2020 2,37x
Capitalization 191 M
Chart ABIVAX
Duration : Period :
Abivax Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABIVAX
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 27,32  €
Last Close Price 16,26  €
Spread / Highest target 140%
Spread / Average Target 68,0%
Spread / Lowest Target -19,4%
EPS Revisions
Managers
NameTitle
Hartmut J. Ehrlich Chief Executive Officer
Philippe Pouletty Chairman
Didier Blondel Chief Financial Officer & Secretary
Didier Scherrer Vice President-Research & Development
Jean-Marc Steens Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABIVAX37.33%213
IQVIA HOLDINGS INC.24.69%28 106
LONZA GROUP32.08%25 344
INCYTE CORPORATION43.91%19 711
SEATTLE GENETICS, INC.100.97%19 516
CELLTRION, INC.--.--%18 622